Insider · CIK 0001796309
Peter Salzmann
Files at IMVT (Immunovant, Inc.). First filing Oct 11, 2024, latest Apr 17, 2025.
Peter Salzmann files SEC Form 4 as CEO and director at IMVT (Immunovant, Inc.). Since Oct 11, 2024, Peter Salzmann has reported 0 open-market buys worth $0 and 8 open-market sells worth $2.0M, the latest filed on Apr 17, 2025.
A track record needs three past buys with six months of prices behind them; Peter Salzmann has 0, so none is measured yet.
The newest scored trade: sold $124k of IMVT on Apr 16, 2025, filed Apr 17, 2025, scored 50 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IMVT: Immunovant, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Immunovant, Inc. | $124k 8,321 shares | -1% | +12% from low-53% from high | |
| 55Moderate | Immunovant, Inc. | $365k 28,094 shares | -2% | +12% from low-53% from high | |
| 54Moderate | Immunovant, Inc. | $322k 15,439 shares | -2% | - | |
| 52Moderate | Immunovant, Inc. | $209k 8,767 shares | -1% | - | |
| 50Moderate | Immunovant, Inc. | $123k 5,105 shares | -1% | - | |
| 56Moderate | Immunovant, Inc. | $425k 16,692 shares | -2% | - | |
| 53Moderate | Immunovant, Inc. | $262k 9,095 shares | -1% | - | |
| 51Moderate | Immunovant, Inc. | $132k 4,460 shares | -0% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2025 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -8,321 | $14.89 | $124k | 1,178,191 | Apr 17, 2025 |
| Apr 9, 2025 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -28,094 | $12.99 | $365k | 1,186,512 | Apr 11, 2025 |
| Apr 1, 2025 | IMVT Immunovant, Inc. | AGrant or award Common Stock | +265,820 | $0.00 | $0 | 1,214,606 | Apr 3, 2025 |
| Apr 1, 2025 | IMVT Immunovant, Inc. | AGrant or award Stock Option (right to buy)derivative | +374,395 | $0.00 | $0 | 374,395 | Apr 3, 2025 |
| Feb 19, 2025 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -15,439 | $20.86 | $322k | 948,786 | Feb 21, 2025 |
| Jan 15, 2025 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -8,352 | $23.81 | $199k | 964,640 | Jan 17, 2025 |
| Jan 15, 2025 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -415 | $24.19 | $10k | 964,225 | Jan 17, 2025 |
| Jan 8, 2025 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -5,105 | $24.10 | $123k | 972,992 | Jan 10, 2025 |
| Nov 20, 2024 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -16,692 | $25.45 | $425k | 978,097 | Nov 22, 2024 |
| Oct 16, 2024 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -9,095 | $28.79 | $262k | 994,789 | Oct 18, 2024 |
| Oct 9, 2024 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -4,460 | $29.56 | $132k | 1,003,884 | Oct 11, 2024 |
Questions about Peter Salzmann
Answered from the filings on this page, as of the latest one.
Is Peter Salzmann buying or selling?
Not in the last 12 months. Peter Salzmann's latest open-market trade on SEC Form 4 was sold $124k of IMVT on Apr 16, 2025.
How did Peter Salzmann's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter Salzmann has 0.
Where does Peter Salzmann file Form 4?
Peter Salzmann has filed Form 4 at IMVT (Immunovant, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.